HBOT Conversations:
Elena Schertz & Extivita RTP
Elena Schertz, NP of Extivita-RTP in North Carolina, discusses how her clinic is actively healing the injured and sick with hyperbaric oxygen therapy (HBOT), including veterans, sports athletes and COVID long-haulers. She explains the proven benefits of HBOT – what it is, who are candidates for the therapy, and how each session saturates a patient’s blood plasma with oxygen for ultimate healing powers.
Extivita-RTP offers a positive environment for healing, and she encourages anyone seeking a better quality of life to come visit them and experience the wonder of hyperbaric oxygen therapy.
Watch the Podcast
HBOT News podcast host, Edward diGirolamo, talks with guest, Elena Schertz, NP of Extivita-RTP, about how her clinic is actively healing the injured and sick with hyperbaric oxygen therapy (HBOT), including veterans, sports athletes and COVID long-haulers. She explains the proven benefits of HBOT – what it is, who are candidates for the therapy, and how each session saturates a patient’s blood plasma with oxygen for ultimate healing powers.
Elena reveals their successes treating TBI and PTSD, and why the therapies at Extivita are even leading to the patient’s elimination of suicidal thoughts. Since veterans are at high risk of suicide due to the grave nature of combat, priority is being taken to treat these American heroes with HBOT at low or no cost. North Carolina’s veteran funding is discussed, while Elena expresses her hope that the state will eventually expand funding to include other beneficial therapies.
The topic of treating COVID long-haulers arise, and Elena makes a claim with absolute certainty that 99% of the COVID long-haulers who come through their doors are significantly better after going through HBOT sessions and nutritional IV regiments, with 95% of them eventually returning to their baseline.
Elena ends the podcast interview raving about her experienced clinical staff, explaining how they celebrate every milestone with their patients relishing in the rewards of making a difference and saving lives. They offer a positive environment for healing, and she encourages anyone seeking a better quality of life to come experience Extivita-RTP and the wonder of hyperbaric oxygen therapy.
Guest
Elena Schertz, NP - Clinic Manager at Extivita RTP
Elena attained her Bachelors of Science in Nursing from Michigan State University and received her Masters of Science in Nursing from Simmons University in Boston, MA. She has been practicing integrative medicine since 2010 and is currently working on her certification in functional medicine from the Institute of Functional Medicine.
Elena worked as a nurse in the pediatric oncology, cardiac, and surgical units at UNC hospitals for 15 years before deciding to work in integrative medicine. After years of working as a nurse, she decided to pursue her graduate degree, completing her masters with honors. She is board certified as a Family Nurse Practitioner (FNP) through the American Nurses Credentialing Center.
Elena’s passion for integrative medicine comes from her knowledge that the mind, body and psych/social/spiritual systems are not separate. The focus of Elena’s practice is to approach each of her patient’s healing process from the perspective of the whole, supported and grounded in safety and evidence-based medicine. She also maintains close consultative relationships with experts in the field to promote and enhance wellness for her patients. Elena joined the wonderful Extivita team in March 2019 and is thrilled to be a part of advancing health and wellness through hyperbaric medicine.
Extivita-RTP – Hyperbaric Oxygen Therapy Clinic
2012-D TW Alexander Drive
Durham, NC 27709
919-354-3775
919-354-3776
contact@extivita.org
https://www.extivita.org/
Subscribe Now, It’s Free !
Recent HBOT News
Healing under pressure: Inside a military hyperbaric chamber
At 16, she had a stroke. At 17, her town burned in the Camp Fire. Now, as her community rebuilds, she's healing thanks to hyperbaric therapy. SACRAMENTO, Calif — February 2, 2017, started off as an ordinary day for the Pipkin Family. Patrick and Stacey Pipkin just...
Clinical Trial – High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC),
which may evolve to acute chest syndrome (ACS), the most common cause of death among adult
patients with SCD. Currently, there is no safe and effective treatment to abort VOC or
prevent secondary ACS. Management of VOC mostly involve a symptomatic approach including
hydration, analgesics, transfusion, and incentive spirometry, which was investigated in a
very limited number of patients (<30).
The polymerisation of HbS is one major feature in the pathogenesis of vaso-occlusion. Among
factors determining the rate and extent of HbS polymer formation, the hypoxic stimulus is one
of the most potent and readily alterable. Current guidelines recommend oxygen therapy in
patients with VOC in order to maintain a target oxygen saturation of 95%. Low-flow nasal
oxygen (LFNO) is routinely used to achieve this normoxia approach, particularly in patients
at risk of secondary ACS because they may experience acute desaturation. In contrast, various
case series suggest a potential beneficial role of intensified oxygen therapy targeting
hyperoxia for the management of VOC, particularly with the use of hyperbaric oxygen, but the
latter is difficult to implement in routine clinical practice.
A recent high-flow nasal oxygen (HFNO) technology allows the delivery of humidified gas at
high fraction of inspired oxygen (FiO2) through nasal cannula. The FiO2 can be adjusted up to
100% (allowing hyperoxia that may reverse sickling) and the flow can be increased up to 60
L/min (which generates positive airway pressure and dead space flushing, that may prevent
evolution of VOC towards ACS by alleviating atelectasis and opioid-induced hypercapnia). In
patients with acute respiratory failure, HFNO has been shown to improve patient's comfort,
oxygenation, and survival as compared to standard oxygen or non-invasive ventilation.
The aim of the present study is to test the efficacy and safety of HFNO for the management of
VOC and prevention of secondary ACS. The investigators will use a multi-arm multi-stage
(MAMS) design to achieve these goals. HFNO will be delivered through AIRVO 2 (Fisher and
Paykel Healthcare, New Zealand), a device that incorporates a turbine allowing its use in
hospital wards.
Clinical Trial – Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are
considered eligible for allogeneic stem cell transplant by the transplant team at WCI (Wilmot
Cancer Institute)will be enrolled in the study. Patients will receive Melphalan on day -2 and
HBO (Hyperbaric Oxygen) therapy on day 0 of the transplant. After neutrophil recovery is
documented, the patients will be seen in clinic at least weekly through day +100.